Mednet Logo
HomeHematologyQuestion

For a patient who has core binding factor AML but also a small FLT3-ITD mutation detected, do you proceed with allo transplant or only HiDAC consolidation after achieving CR from induction chemotherapy?

1 Answers
Mednet Member
Mednet Member
Medical Oncology · West Virginia University Cancer Institute

My CBF patients with FLT3-ITD who have achieved CR1 following induction have done quite well with high dose cytarabine consolidation and I cannot recall any of them who have required transplant. Historically, I have managed my CBF-AML patients with FLT3-ITD the same as those without FLT3-ITD since t...

Register or Sign In to see full answer